ArticleCureus2025
Managing Hashimoto's Encephalopathy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Morgagni-Stewart-Morel Syndrome Presenting as Acute Neurological and Respiratory Distress.European journal of case reports in internal medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hashimoto's encephalopathy (HE), also known as steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT), is a rare condition associated with thyroid autoimmunity. Characterized by cognitive decline, seizures, and neuropsychiatric symptoms, HE remains poorly understood and poses diagnostic challenges due to its variable criteria presentations and overlap with other conditions. Diagnosis typically involves clinical criteria, emphasizing encephalopathy in conjunction with positive thyroid antibodies, exclusion of alternative causes, and responsiveness to corticosteroid treatment. We present the case of a 76-year-old male patient admitted with acute gait disturbance and disorientation, later developing seizures and respiratory failure. Initial imaging demonstrated diffuse cortical atrophy, nonspecific white matter ischemic changes, and a right frontal meningioma. While infections and metabolic causes were ruled out, significantly elevated anti-thyroid peroxidase (ATPO) antibodies suggested HE. Corticosteroid therapy was administered with methylprednisolone pulse treatment (1 g/day for three days), leading to substantial neurological improvement and stabilization. Despite some residual ataxic symptoms, the patient's overall functional and cognitive status showed significant recovery. This case emphasizes the importance of considering HE in patients with unexplained encephalopathy and positive thyroid antibodies. Early intervention with corticosteroids can be vital in preventing lasting neurological damage. Continued research into HE is essential to refine diagnostic criteria, enhance differential diagnosis, and establish evidence-based treatment protocols that optimize patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.